Rosetta, UC Davis collaborate on miRNA biomarkers
PHILADELPHIA—Rosetta Genomics recently announced a new collaboration with the University of California, Davis (UC Davis) to develop and validate a microRNA profile for muscle-invasive bladder cancer (MI-BC) that can predict patient response to neoadjuvant chemotherapy. Approximately 30 percent of bladder cancer patients manifest or will develop MI-BC, for which the five-year survival rate is about 50 percent. Additionally, only 50 percent of MI-BC patients respond to chemotherapy, and the other option, cystectomy (bladder removal) has not improved survival rates significantly. Through the collaboration, UC Davis' researchers gain continued use of Rosetta's platforms and microRNAs to discover new biomarkers. Researchers have already begun studying 55 patients with MI-BC at UC Davis Cancer Center who have received neoadjuvant chemotherapy. No financial details for the collaboration have been disclosed.